While there is no true cure for heart failure, today’s therapies and monitoring options help more people than ever to manage their heart failure, live longer and improve their quality of life.
Abbott continues to set new standards with the world’s most comprehensive portfolio of innovative, evidence-based solutions for heart failure therapy supported by a deep commitment to the advancement of heart failure therapies.
Heart
transplant2
HeartMate 3™
LVAD1
Based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.
HEART TRANSPLANTATION
Patients with advanced or end-stage heart failure have only a few therapy options available. Heart transplantation may be the treatment of choice in carefully selected patients. There is however a difference between the number of patients eligible for a heart transplant and the number of suitable donors. The number of donors is insufficient to meet the demand.
619
Heart
transplants1
1.158
People on the active
heart waiting list2
FIND OUT MORE:
LEFT VENTRICULAR ASSIST DEVICES
Time may run out for patients put on the waiting list, to receive a heart transplantation. Their condition may require earlier intervention than a donor heart would become available. Some of these patients may benefit from a left ventricular assist device (LVAD), an implanted heart pump which can help the heart pump oxygen-rich blood throughout the body and potentially improve the symptoms of advanced heart failure.5
FIND OUT MORE:
TV
- Mehra MR, Uriel N, Naka Y, et al. A fully magnetically levitated left ventricular assist device—final report. N Engl J Med. 2019;380(17):1618–1627. doi.org/10.1056/NEJMoa1900486.
- Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth heart transplantation report—2018; focus theme: multiorgan transplantation. J Heart Lung Transplant. 2018;37(10):1155–1168. doi.org/10.1016/j.healun.2018.07.022.
- Eurotransplant Annual Report 2022. ETP_AR2022_LR_def.pdf (eurotransplant.org). Accessed July 2023.
- Eurotransplant Annual Report 2022. ETP_AR2022_LR_def.pdf (eurotransplant.org). Accessed July 2023.
- Mehra MR, Goldstein DJ, Uriel N, et al. Two-year outcomes with a magnetically levitated cardiac pump in heart failure. N Engl J Med. 2018;378:1386–1395. doi.org/10.1056/NEJMoa1800866.